Journal of Pediatric Ophthalmology and Strabismus

Short Subjects 

RETRACTED: Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant

Muhammad Musab Shamim, BS; Heather Monitz Weissman, MD; Zaina Nabil Al-Mohtaseb, MD

Abstract

This article has been retracted at the request of the author. I would like to formally request that the article entitled, “Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant” (volume 55, pp. e30-e32; doi: 10.3928/01913913-20180806-01) be retracted. Although our group was involved in the initial treatment of the patient described, we were not involved in the Investigational New Drug Applications administered by the Indiana Hemophilia & Thrombosis Center and Vanderbilt University after the patient’s family moved out of state, and therefore do not have access to the full details of the drug data from the two biopharmaceutical companies that manufacture these products. Zaina Nabil Al-Mohtaseb, MD doi:10.3928/01913913-20181220-02

Abstract

This article has been retracted at the request of the author. I would like to formally request that the article entitled, “Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant” (volume 55, pp. e30-e32; doi: 10.3928/01913913-20180806-01) be retracted. Although our group was involved in the initial treatment of the patient described, we were not involved in the Investigational New Drug Applications administered by the Indiana Hemophilia & Thrombosis Center and Vanderbilt University after the patient’s family moved out of state, and therefore do not have access to the full details of the drug data from the two biopharmaceutical companies that manufacture these products. Zaina Nabil Al-Mohtaseb, MD doi:10.3928/01913913-20181220-02
This article has been retracted at the request of the author. I would like to formally request that the article entitled, “Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant” (volume 55, pp. e30-e32; doi: 10.3928/01913913-20180806-01) be retracted. Although our group was involved in the initial treatment of the patient described, we were not involved in the Investigational New Drug Applications administered by the Indiana Hemophilia & Thrombosis Center and Vanderbilt University after the patient’s family moved out of state, and therefore do not have access to the full details of the drug data from the two biopharmaceutical companies that manufacture these products. Zaina Nabil Al-Mohtaseb, MD doi:10.3928/01913913-20181220-02
Authors

From Baylor College of Medicine, Houston, Texas (MMS, ZNA); Atlanta Ophthalmology Associates, Atlanta, Georgia (HMW); Ben Taub General Hospital, Houston, Texas (ZNA); and MD Anderson Cancer Center, Houston, Texas (ZNA).

The authors have no financial or proprietary interest in the materials presented herein.

Correspondence: Zaina Nabil Al-Mohtaseb, MD, Cullen Eye Institute, Baylor College of Medicine, 6565 Fannin NC 205, Houston, TX 77030. E-mail: zaina@bcm.edu

Received: April 22, 2018
Accepted: July 25, 2018
Posted Online: August 29, 2018

10.3928/01913913-20180806-01

Sign up to receive

Journal E-contents